This article is mentioned in:

Introduction

Asthma is one of the major chronic and non-communicable syndromes in both children and adults, whereby ~334 million people suffer from this disease worldwide (1). The pathophysiological process of asthma involves several types of cells and cellular components, among which airway remodeling is a well-known characteristic caused by recurrent injury and repair processes initiated by chronic inflammation (2). As a chronic inflammatory disorder of the respiratory air passages, asthma may initially be reversible but progresses into an irreversible state due to airway remodeling (3). Moreover, the prevalence of asthma has been increasing worldwide with a yearly rate of 1.8%, and 300 million people affected are in mainland China, causing a substantial economic burden (4,5); therefore, understanding the precise pathophysiology of asthma is paramount to achieve optimal management.

Recent research has focused on the identification of candidate pharmacologically active ingredients in natural herbs to prevent and treat asthma (6-9). Glycyrrhizic acid (GA), also known as glycyrrhizin, is one of the most important bioactive constituents isolated from the traditional Chinese herb Glycyrrhiza uralensis, which has been demonstrated to display multiple pharmacological activities, such as anticancer, antiviral and anti-inflammatory effects (10-12). In addition, the number of studies focusing on the protective effects of GA against asthma have increased; however, its underlying molecular mechanism involved in asthma remains unknown (13,14).

Research has reported that targeting the transforming growth factor-β1 (TGF-β1)/Smad signaling pathway may provide a novel therapeutic method for asthma airway remodeling (15). TGF-1 is considered the main regulator of airway remodeling in asthma and directly affects the deposition of collagen in the airway wall (16). The Smad protein, an important member of the TGF-β signal transduction system, is central to the signal transduction pathway (17,18). However, whether GA attenuates asthma symptoms through the TGF-β1/Smad signaling pathway remains unclear. Thus, the present study aimed to investigate the function of GA on the TGF-1/Smad signaling pathway in airway inflammation and remodeling in ovalbumin (OVA)-induced asthma mouse models, in order to provide a theoretical background for asthma management.

Materials and methods

Experimental animals

A total of 50 healthy female BALB/c mice (20-22 g) aged 10-12 weeks were obtained from Hunan SJA Laboratory Animal Co., Ltd. (Changsha, China) and housed in the Laboratory Animal Center of Medical College of Hunan Normal University. All mice were fed in an animal house at a relative humidity of 40-60%, temperature of 22-26˚C and sufficient light. In addition, the mice had free access to food and water in a controlled environment (sterile food and drinking water in accordance with room pressure standard). All animal experiments were approved by the local Ethics Committee of Beijing University of Chinese Medicine and performed in accordance with the Guide for the Care and Use of Laboratory Animals (19).

Animal grouping and model establishment

A total of 50 female mice were randomly assigned into five groups (10 mice/group), as follows: Blank group, asthma group, GA group (80 mg/kg; cat. no. 1295888; Sigma-Aldrich; Merck KGaA), dexamethasone group (2 mg/kg; cat. no. D1756; Sigma-Aldrich; Merck KGaA) and the GA + TGF-β1 group. During the course of asthma sensitization, the mice in the asthma, GA, dexamethasone and GA + TGF-β1 groups were intraperitoneally injected with 0.2 ml sensitizing liquid supplemented with 200 µg/ml OVA (Sigma-Aldrich; Merck KGaA) and 20 mg/ml aluminum hydroxide suspension (Chengdu Kelong Chemical Co., Ltd.), at days 0, 7 and 14. In addition, mice in the GA + TGF-β1 group were intraperitoneally injected with exogenous recombinant TGF-β1 (0.1 µg/rat; 100-21C; PeproTech, Inc.). Mice in the blank group were simultaneously given intraperitoneal injections of the same amount of normal saline solution (0.7%) as the control group. After the mice were in phase excitation from the 14th day, the OVA solution (0.2 ml) was delivered into the noses of mice in the asthma, GA, dexamethasone and GA + TGF-β1 groups to construct a chronic asthma model, and the blank group received a continuous nasal drip with the same amount of normal saline. The excitation period lasted for 6 days.

In the excitation phase, mice were anesthetized by intraperitoneal injection with 250 mg/kg tert butyl alcohol (cat. no. 471712; Sigma-Aldrich, Merck KGaA) and tribromethanol (cat. no. T48402; Sigma-Aldrich, Merck KGaA) mixture (diluted with PBS, x40). The OVA solution was delivered to the nose of mice using a 50 µl micropump (Shanghai Elab Scientific Instruments). At the time of excitation, mice in the GA and dexamethasone groups were intraperitoneally injected with GA and dexamethasone 30 min before the nasal drip according to 80 and 2 mg/kg standards (20), respectively. The general conditions of the mice in each group, including their appetites, fur, mental conditions, weight changes and airway pathological changes were observed and recorded every day.

Preparation for lung tissue slices

All mice were anesthetized by injection with 250 mg/kg tert butyl alcohol (cat. no. 471712; Sigma-Aldrich, Merck KGaA) and tribromethanol (cat. no. T48402; Sigma-Aldrich, Merck KGaA) mixture ~24 h after model establishment. Subsequently, their eyeballs were fully exposed, and blood was collected via orbital blood sampling and transferred into a sodium citrate anticoagulation tube. The tube was centrifuged for 10 min at room temperature at 1,000 x g prior to collection of the supernatant and storage at -20˚C.

The mice were sacrificed by cervical vertebrae dislocation, and the thoracic cavity was immediately opened to expose the lung tissues. Normal saline (0.7%) was injected into the lung tissues for perfusion and rinsed using 10 ml injection syringe until the lung tissues blanched. The right lung tissues were rapidly extracted and placed in liquid nitrogen for storage, whereas the left lung tissues were harvested and fixed in 4% paraformaldehyde for 24 h (room temperature) to prepare paraffin sections. The tissue sections were subsequently subjected to hematoxylin and eosin (H&E) and Masson staining.

H&E staining

The paraffin-embedded tissue samples were cut into 5-µm-thick sections and deparaffinized in xylene Ⅰ and xylene II for 15 min each (room temperature), with an ethanol wash (two times, 5 min each) at room temperature. The tissue sections were subsequently rehydrated in a descending ethanol series (95, 80 and 70%; 5 min each) and washed two times with deionized water. The paraffin sections were dewaxed, stained with hematoxylin for 10 min (room temperature), washed in running water for 5 min followed by differentiation in 1% hydrochloric acid ethanol solution for 30 sec, and re-washed in running water. Tissue sections were subsequently stained with 1% eosin for 30 sec at room temperature and washed in running water, prior to rehydration in an ethanol series (95, 95, 100 and 100%; 1 min each) and cleared in xylene (two times, 3 min each). Tissue sections were sealed with a neutral resin seal sheet for observation under a fluorescence microscope (DM3000 and DM3000 LED; Leica Microsystems GmbH).

Masson staining

The paraffin-embedded tissue samples were cut into 5-µm thick sections and deparaffinized in xylene Ⅰ and xylene II for 15 min each, with an ethanol wash (two times, 5 min each) at room temperature. The tissue sections were subsequently rehydrated in a descending an ethanol series (95, 80 and 70%, 5 min each), with repeated cleaning cycles. Tissue sections were subsequently stained with Masson trichrome stain (Beijing Solarbio Science & Technology Co., Ltd.) for 5-10 min (room temperature) and rinsed with 2% acetic acid solution, prior to differentiation in 1% molybdophosphoric acid aqueous solution for 3-5 min. Aniline solution was subsequently added to the tissue sections for 5 min, followed by a final rinse with 0.2% glacial acetic acid solution. Tissue sections were rehydrated in an ethanol series (95, 95, 100 and 100%; 1 min each) and cleared in xylene (two times, 3 min each), prior to sealing with a neutral resin for observation using an optical microscope (20X objective). The thickness of the airway wall (Wat, µm2), smooth muscle layer (Wam, µm2), thickness of the inside airway wall (Wai, µm2), collagen deposition under the basement membrane (Wcol, µm2) and basement membrane perimeter (Pbm) were measured using Image-Pro Plus 6.0 (IPP 6.0) software (Media Cybernetics, Inc.).

Periodic acid-Schiff (PAS) staining

Goblet cell hyperplasia was assessed via PAS staining. The paraffin-embedded lung tissues (5-µm-thick) were deparaffinized in xylene Ⅰ and II for 20 min, and rehydrated in ethyl alcohol Ⅰ, ethyl alcohol II and 75% alcohol for 5 min each, prior to rinsing with tap water for 2 min. Tissue sections were subsequently treated with periodic acid for 15 min and rinsed with running water for 2 min, prior to staining with Coleman's Schiff stain at room temperature in the dark for 30 min. Sections were counterstained with hematoxylin and differentiated in 1% hydrochloric acid ethanol (rinsed after each step). Tissue sections were rehydrated in ethyl alcohol Ⅰ, ethyl alcohol II and ethyl alcohol III (5 min each), cleared in xylene Ⅰ and II (5 min each) and sealed in neutral resin prior to observation under an optical microscope (20X objective). The PAS-positive area (APAS+) and basement membrane perimeter (Pbm) was determined using IPP 6.0 software. The degree of goblet cell hyperplasia was represented as APAS+/Pbm (µm2/µm).

Enzyme-linked immunosorbent assay (ELISA)

ELISA was used to detect inflammatory factors in serum of rats. The levels of inflammatory cytokines interleukin (IL)-4, IL-5, IL-13 and IL-17 in mouse serum in each group were determined using the following Mouse ELISA kits: IL-4 (cat. no. BMS613), IL-5 (cat. no. EMIL5ALPHA), IL-13 (cat. no. BMS6015) and IL-17 (cat. no. BMS6001; all purchased from Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocols. The absorbance value (OD value) of each well was measured at a wavelength of 450 nm, using a multimode microplate (Synergy 2; BioTek Instruments, Inc.).

Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was extracted from lung tissues using TRIzol® reagent (Thermo Fisher Scientific, Inc.), and the purity and concentration of RNA were detected using a multimode microplate (BioTek Instruments, Inc.). Following quantification, total RNA was reverse transcribed into cDNA using a Path-ID™ Multiplex One-Step RT-PCR kit (cat. no. 4442136; Applied Biosystems; Thermo Fisher Scientific, Inc.). qPCR with SYBR-Green detection was subsequently performed using a CFX Connect fluorescence quantitative PCR detection system (Bio-Rad Laboratories, Inc.). The primer sequences are presented in Table I. The following thermocycling conditions were used for qPCR: Initial denaturation at 95˚C for 10 min, denaturation at 95˚C for 10 sec, annealing at 60˚C for 20 sec and a final extension at 72˚C for 34 sec for 40 total cycles. Relative mRNA levels were quantified using the 2-ΔΔCq method (21) and normalized to the internal reference gene GAPDH.

Table I Primer sequences used for quantitative PCR.

Table I

Primer sequences used for quantitative PCR.

Primer	Sequence (5'-3')
TGF-β1	F: GTGTGGAGCAACATGTGGAACTCTA
	R: TTGGTTCAGCCACTGCCGTA
SMAD2	F: CCACTACCAGAGGGTGGAGA
	R: TAACTGGCTGCAATCCAAG
SMAD7	F: AGGCATTCCTCGGAAGTCAA
	R: TGGACAGTCTGCAGTTGGTTTG
GAPDH	F: GTCGATGGCTAGTCGTAGCATCGAT
	R: TGCTAGCTGGCATGCCCGATCGATC

[i] TGF-β1, transforming growth factor-β1; F, forward; R, reverse.

Western blotting

The right lung tissue of mice was ground into a powder under liquid nitrogen and subsequently lysed using lysis buffer for 30 min on ice. Cells were centrifuged at 7,500 x g for 10 min at 4˚C. The supernatant was collected, and total protein was quantified using a bicinchoninic acid assay (Vazyme Biotech Co., Ltd.) and 30 µg protein/lane was separated via SDS-PAGE on a 10% gel. The separated proteins were subsequently electroblotted onto polyvinylidene difluoride membranes (EMD Millipore) and blocked with 5% nonfat milk at room temperature for 1 h. The membranes were incubated with primary antibodies against: Rabbit anti-mouse TGF-β1 (cat. no. 3711S; 1:1,000; Cell Signaling Technology, Inc.), Smad2 (cat. no. 5339S; 1:1,000; Cell Signaling Technology, Inc.) and Smad7 (cat. no. ab216428; 1:1,000; Abcam) overnight at 4˚C. Membranes were washed three times with TBST (10 min/wash). Following the primary incubation, membranes were incubated with horseradish peroxidase labeled goat anti-rabbit IgG secondary antibody (1:5,000; cat. no. CW0103S; Beijing ComWin Biotech Co., Ltd.) at room temperature for 1 h. Membranes were re-washed three time with TBST (10 min/wash), and protein bands were visualized using a chemiluminescence imaging system (Tanon Science and Technology Co., Ltd.) and normalized to the internal reference gene GAPDH.

Statistical analysis

Every experiment was replicated thrice. Statistical analysis was performed using SPSS 17.0 software (SPSS, Inc.) and data are presented as the mean ± standard deviation. t-test was used for comparison between two groups and one-way ANOVA was used for comparisons among multiple groups. Homogeneous data were analyzed using the least significant difference test (three groups) or Tukey's post hoc test (more than three groups). Nonhomogeneous data were analyzed using Kruskal-Wallis and Dunn's post hoc tests. P<0.05 was considered to indicate a statistically significant difference.

Results

Establishment of chronic asthma mouse models

Following sensitization and excitation by OVA, mice in the asthma, GA and dexamethasone groups developed the following symptoms: Shortness of breath, irritability, incontinence, rapid breathing, irregular breathing rhythm, visibly trembling limbs, cyanosis, cough and decreased activity. Conversely, no obvious symptoms were observed among mice in the blank group. Notably, mice in the GA and dexamethasone groups did not vary to a great extent; however, mice in the asthma group had severe symptoms compared with those in the GA and dexamethasone groups. No mice died during this experiment.

The results of H&E staining are presented in Fig. S1A, which exhibited no remarkable airway inflammation and lung morphology changes in the blank group. However, mice in the asthma group had a significantly thicker airway wall and airway smooth muscle, a broadened strata submucosa, mucosal epithelial hyperplasia and heightened mucus secretion (P<0.01; Fig. S1A and B). In addition, mice in each group were scored in compliance with the scoring directive (Table II) (22), which revealed notable airway inflammation, inflammatory cell infiltration and airway remolding in mice with OVA-induced asthma compared with mice in the blank group (P<0.01; Fig. S1B and C).

Table II Standard of inflammation score.

Table II

Standard of inflammation score.

Score	Airway inflammatory cells	Alveolar inflammation
0	No cells	No infection
1	A few cells	A few macrophages in alveoli
2	A ring of 1 cell layer deep	Slight thickening of alveolar walls, more macrophages and eosinophils in alveoli
3	A ring of 2-4 cells deep	Significant thickening of alveolar walls, multinucleated giant cells and eosinophils in 30-50% of alveoli involved
4	A ring of >4 cells deep	Significant thickening of alveolar walls, multinucleated giant cells and eosinophils in >50% of alveoli involved
5	-	Alveolar consolidation

Masson staining stained the collagen fiber blue, the muscle fiber cytoplasm red and the nucleus blue/brown. Following Masson staining of the lung tissues, the degree of airway wall thickness (Wat, µm2), smooth muscle layer (Wam, µm2), thickness of the inside airway wall (Wai, µm2) and collagen deposition under the basement membrane (Wcol, µm2) were measured and standardized to the perimeter of the basement membrane (Pbm). The results demonstrated that mice in the asthma group exhibited effectively enhanced deposition of airway collagen fiber in addition to elevated Wat/Pbm, Wam/Pbm, Wai/Pbm and Wcol/Pbm, compared with mice in the blank group (P<0.01; Fig. S1A and D).

PAS staining was performed to detect goblet cells, and the results demonstrated that there were no PAS-positive goblet cells in the blank group. Conversely, a large number of PAS-positive goblet cells were observed in the airway epithelium of asthmatic mice, causing excessive secretion of airway mucus (Fig. S1A). The PAS-positive area (APAS+/Pbm) of the membrane length (µm) was quantitatively measured and the results demonstrated that APAS+/Pbm significantly increased in OVA-exposed mice compared with the blank group (P<0.01; Fig. S1E). Taken together, these results exhibited successful establishment of OVA-induced chronic asthma models.

GA attenuates lesions in airways and airway collagen deposition in mice with chronic asthma

As presented in Fig. 1A, mice in the GA and dexamethasone groups exhibited modest airway inflammation, and decreased airway wall and airway smooth muscle layers compared with the asthma group. In addition, lesions in all groups of mice were scored in compliance with the scoring directive (Table II). The results demonstrated that mice in the GA and dexamethasone groups had mitigated airway inflammation, inflammatory cell infiltration and airway remolding compared with the asthma group (P<0.05 and P<0.01; Fig. 1B and C).

Figure 1 GA prevents lesions in airways and airway collagen deposition in mice with ovalbumin-induced chronic asthma. (A) The pathological changes in the airways and alveolar tissues of mice were determined via H&E, Masson and PAS staining (magnification, x200). (B) Inflammation score of the airway and airway side in mice of each group. (C) Inflammation score of the pulmonary alveoli in mice of each group. (D) The levels of Wat/Pbm, Wam/Pbm, Wai/Pbm and Wcol/Pbm were determined via Masson staining. (E) The PAS-positive area per total area was measured. *P<0.05, **P<0.01 vs. asthma group. GA, glycyrrhizic acid; H&E, hematoxylin and eosin; PAS, periodic acid-Schiff.

Masson staining demonstrated that mice in the GA and dexamethasone groups exhibited elevated deposition of airway collagen fiber, as well as mitigated Wat/Pbm, Wam/Pbm, Wai/Pbm and Wcol/Pbm compared with mice in the asthma group (P<0.05; Fig. 1A and P<0.01; Fig. 1D). PAS staining demonstrated that the number of PAS-positive goblet cells significantly decreased in the GA and dexamethasone groups compared with the asthma group, suggesting that GA and dexamethasone decreased airway mucus secretion in asthmatic mice (P<0.05; Fig. 1A and P<0.01; Fig. 1E).

GA suppresses inflammation in mice with chronic asthma

ELISA was performed to detect the serum levels of inflammatory cytokines from each group. As presented in Fig. 2, the levels of IL-4, IL-5, IL-13 and IL-17 significantly increased in the asthma group compared with the blank group (P<0.01), while the GA and dexamethasone groups exhibited lower levels of IL-4, IL-5, IL-13 and IL-17 compared with the asthma group (P<0.05). Collectively, these results exhibit the anti-inflammatory role of GA in mice with chronic asthma.

Figure 2 GA suppresses inflammation in mice with ovalbumin-induced chronic asthma. The serum levels of (A) IL-4, (B) IL-5, (C) IL-13 and (D) IL-17 in mice in the asthma, GA and dexamethasone groups were detected via the enzyme-linked immunosorbent assay. **P<0.01 vs. blank group; #P<0.05 vs. asthma group. GA, glycyrrhizic acid; IL, interleukin.

GA inhibits the TGF-β1/Smad signaling pathway in OVA-challenged mice with asthma

mRNA and protein levels of TGF-β1, Smad2 and Smad7 in the lung tissues of mice in each group were assessed via western blot and RT-qPCR analyses. The results demonstrated that both mRNA and protein levels of TGF-β1 and Smad2 significantly increased in the asthma, GA and dexamethasone groups (P<0.05; Fig. 3A, B, D and E), while there was an obvious decrease in Smad7 mRNA and protein levels compared with the blank group (P<0.05; Fig. 3C-E).

Figure 3 Expression levels of TGF-β1, Smad2 and Smad7 in lung tissues of mice. mRNA levels of (A) TGF-β1, (B) Smad2 and (C) Smad7 in mouse lung tissues of each group were detected via reverse transcription-quantitative PCR analysis. (D) Protein levels of TGF-β1, Smad2 and Smad7 in mouse lung tissues of each group were detected via western blot analysis. (E) The gray value of protein bands among groups was assessed. *P<0.05 vs. blank group; #P<0.05 vs. asthma group. TGF-β1, transforming growth factor-β1.

The levels of TGF-β1 and Smad2 significantly decreased (P<0.05; Fig. 3A, B, D and E), whereas Smad7 was strongly expressed in the GA and dexamethasone groups (P<0.05; Fig. 3C-E) compared with the asthma group. Taken together, these results suggest that GA ameliorates airway inflammation and remodeling by downregulating the TGF-β1/Smad signaling pathway in asthma.

Effects of exogenous recombinant TGF-β1 on the regulation of GA in asthmatic mice

To further validate the association between GA and the GF-β1/Smad signaling pathway on airway inflammation and remodeling, mice with chronic asthma were established by intraperitoneal injection of exogenous recombinant TGF-β1 and GA. As presented in Fig. 4A, mice in the GA + TGF-β1 group had aggravated airway inflammation, as well as thickened airway walls and airway smooth muscle layers compared with the GA group. Inflammation in all groups of mice was scored (Table II), and the results demonstrated that airway inflammation, inflammatory cell infiltration and airway remolding were considerably exacerbated in mice in the GA + TGF-β1 group compared with the GA group (P<0.05; Fig. 4B and C).

Figure 4 Effects of TGF-β1 in asthmatic mice. (A) H&E, Masson and PAS staining (magnification, x200) were performed to determine the pathological changes in the airways and alveolar tissues of mice. (B) Inflammation of the airway and airway side, as well as (C) pulmonary alveoli in mice of each group were detected. (D) Masson staining was performed to determine the levels of Wat/Pbm, Wam/Pbm, Wai/Pbm and Wcol/Pbm. (E) The PAS-positive area per total area was measured. The serum levels of (F) IL-4, (G) IL-5, (H) IL-13 and (I) IL-17 in mice of each group were detected via the enzyme-linked immunosorbent assay. **P<0.01, ***P<0.001 vs. asthma group; #P<0.05, ##P<0.01 vs. GA group. TGF-β1, transforming growth factor-β1; H&E, hematoxylin and eosin; PAS, periodic acid-Schiff; IL, interleukin; GA, glycyrrhizic acid.

Masson staining confirmed that there were decreased deposition of airway collagen fiber coupled with increased Wat/Pbm, Wam/Pbm, Wai/Pbm and Wcol/Pbm in the GA + TGF-β1 group compared with the GA group (P<0.05 and P<0.01; Fig. 4A and D). PAS staining demonstrated that the number of PAS-positive goblet cells significantly increased in the GA + TGF-β1 group compared with the GA group, suggesting that TGF-β1 increased airway mucus secretion in asthmatic mice (P<0.05; Fig. 4A and E). In addition, ELISA was performed to determine the serum levels of inflammatory cytokines in mice treated with GA alone or with both TGF-β1 and GA. The results demonstrated that the levels of IL-4, IL-5, IL-13 and IL-17 significantly increased in the GA + TGF-β1 group compared with the GA group (P<0.05 and P<0.01; Fig. 4F-I). Collectively, these results suggest that the anti-inflammatory role of GA in mice with chronic asthma occurs by downregulating the TGF-β1/Smad signaling pathway.

Discussion

Immense efforts have been made for asthma therapy; however, due to the heterogenicity and complexity of asthma, effectively controlling asthma remains difficult (23). Previous studies have demonstrated that GA ameliorates asthma and other human disease symptoms including septic acute kidney injury, liver injury and lung injury (14,24-26). Thus, the present study aimed to investigate the therapeutic effects of GA on airway inflammation and remodeling in asthmatic mice and determine its underlying molecular mechanism in asthma. Taken together, the results of the present study suggest that GA may exert anti-asthmatic effects in mice by modulating the TGF-β1/Smad signaling pathway.

H&E staining demonstrated an elevated number of airway smooth muscle cells, and the smooth muscle layer was notably thickened in mice following OVA treatment. Consistent with findings of a previous report (27), Masson staining indicated that intrapulmonary bronchial Wat/Pbm, Wam/Pbm, Wai/Pbm and Wcol/Pbm increased in the OVA-sensitized group compared with the blank group. Furthermore, PAS staining demonstrated that there was a large number of PAS-positive goblet cells in the airway epithelium of asthmatic mice. Thus, the present study successfully established an asthma model in mice.

Currently, the anti-inflammatory role of GA has received increasing attention (28,29). In addition, it has been demonstrated that GA can alleviate the symptoms of allergic asthma (30). The results of the present study demonstrated that the ratios of Wat/Pbm, Wam/Pbm, Wai/Pbm and Wcol/Pbm significantly decreased in the GA and dexamethasone groups compared with those in the asthma group. This suggests that GA may suppress increased thickness in the airway wall and smooth muscle, yielding a positive effect on improving airway remodeling. Similarly, the number of PAS-positive goblet cells significantly decreased in the GA and dexamethasone groups in contrast to the asthma group, suggesting that GA and dexamethasone may decrease airway mucus secretion in asthmatic mice. In addition, the levels of IL-4, IL-5, IL-13 and IL-17 were significantly lower in the GA and dexamethasone groups compared with the asthma group, indicating that GA may suppress the inflammatory response in chronic asthma.

Increasing evidence have demonstrated that the TGF-β1/Smad signaling pathway is considered one of the most essential molecular mechanisms for airway remodeling in asthma (15,31-33). TGF-β1 is a profibrotic cytokine that is believed to exert a critical role in chronic asthma (34). The Smad family of proteins is the only proven substrate acted by the TGF-β1 receptor (35), and also the Smad protein has been reported to modulate the intracellular mediators for TGF-β1 signaling (36). In addition, previous studies have reported that TGF-β1 may have several biological effects via the activation of downstream mediators, such as Smad2, Smad3 and Smad4, and TGF-β1 is negatively regulated by Smad7 expression (37-39). The results of the present study demonstrated that TGF-β1 and Smad2 mRNA and protein levels notably increased in mouse lung tissues in each group, while opposite effects were observed following GA treatment. Furthermore, as an inhibitory Smad protein, Smad7 blocks TGF-β signaling through a negative feedback loop (40). The present results showed that Smad7 exerted an inhibitory role in asthmatic mouse, and this inhibitory effect was enhanced by GA treatment. Taken together, GA effectively promoted Smad7 mRNA and protein expression, and downregulated the levels of TGF-β1 and Smad2 in the lung tissues of mice with asthma. Thus, the TGF-β1/Smad signaling pathway may be a novel therapeutic approach for controlling asthma airway remodeling.

The present study also aimed to determine whether the TGF-β1/Smad signaling pathway was implicated in the regulation of GA on airway inflammation and remodeling. A previous study reported that OVA-challenged mouse fibroblasts undergo morphological alterations in response to exogenous TGF-β1 stimulation (41). In the present study, exogenous TGF-β1 in combination with GA were intraperitoneally injected into asthmatic mice to detect airway inflammation and remodeling. As expected, exogenous TGF-β1 significantly increased airway inflammation, inflammatory cell infiltration and airway remolding, accompanied by decreased deposition of airway collagen fiber and increased Wat/Pbm, Wam/Pbm, Wai/Pbm and Wcol/Pbm, which also resulted in the promotion of airway mucus secretion and inflammatory cytokines in asthmatic mice. Taken together, these results suggest that GA inhibits asthma airway remodeling in mice with asthma at least partly via inactivation of the TGF-β1/Smad signaling pathway.

In conclusion, the present study demonstrated that GA is closely associated with chronic asthma development, and its underlying molecular mechanism was investigated. To the best of our knowledge, the present study was the first to demonstrate that GA may suppress chronic asthma, at least in part via the inhibition of TGF-β1 and Smad2, as well as upregulation of Smad7 expression in mice with asthma. Collectively, the results of the present study indicate that GA attenuates airway inflammation and remodeling in asthma mainly through the TGF-β/Smad signaling pathway, suggesting that GA may be used as a medical treatment for chronic asthma. However, the present study was not without limitations. The present findings had only been investigated in vitro and in vivo, and more data are required to validate the results of our study before those treatments yield benefits in the clinic. Prospective studies will perform in vitro experiments and deeper analysis to further substantiate the specific target cells for GA treatment of asthma.

Supplementary Material

Mice with chronic asthma exhibit severe lesions in the airways and more deposited airway collagen fiber. (A) The pathological changes in the airways and alveolar tissues of mice were determined via H&E, Masson and PAS staining (magnification, x200). (B) Inflammation score of the airways and airway side in mice of each group. (C) Inflammation score of the pulmonary alveoli in mice of each group. (D) The levels of Wat/Pbm, Wam/Pbm, Wai/Pbm and Wcol/Pbm were determined via Masson staining. (E) The PAS-positive area per total area was measured. **P<0.01 vs. blank group. H&E, hematoxylin and eosin; PAS, periodic acid-Schiff.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and.or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

ZY and YF conceived the study and designed and performed the experiments. ZY analyzed the data and wrote the manuscript. YF provided critical materials and supervised the study. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All animal experiments were approved by the local Ethics Committee of Beijing University of Chinese Medicine (approval no. A-20190821006) and performed in accordance with the Guide for the Care and Use of Laboratory Animals.

Patients consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References